세 종류의 혈액 검체에서 Samsung LABGEO PT10과 Variant II Turbo의 HbA1c 측정능 비교 평가
Comparing the Efficacy of Samsung LABGEO PT10 and Bio-Rad Variant II Turbo for HbA1c Measurement in Three Types of Blood Samples
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
배경: 당화혈색소(Hemoglobin A1c)는 혈당 조절을 확인하는 좋은 표지자이며, 여러 가지 방법으로 측정할 수 있다. 최근 국내에서 현장검사로서 사용 가능한 LABGEO PT10 (Samsung Electronics, Korea) HbA1c 검사가 개발되었다. 이에, 세 종류의 혈액 검체에서 HbA1c 측정값을 비교 평가하고자 하였다방법: LABGEO PT10에서 측정한 검체별 HbA1c 결과는 Bio-Rad Variant II Turbo (Bio-Rad Laboratories, USA)에서의 측정값을 참고값으로 하여 비교하였다. 세 종류의 검체는 모세혈, EDTA 전혈, 리튬-헤파린 전혈을 준비하였다. 결과: LABGEO PT10에서 측정한 모세혈 HbA1c와 Variant II Turbo에서 측정한 EDTA 전혈 HbA1c 사이의 상관계수(r)는 0.9619였다. 한편, LABGEO PT10에서 측정한 모세혈 HbA1c와 Variant II Turbo에서 측정한 리튬-헤파린 전혈 HbA1c 사이의 상관계수(r)는 0.9619, LABGEO PT10에서 측정한 모세혈 HbA1c와 EDTA 전혈 HbA1c 사이의 상관계수는 0.9697, LABGEO PT10에서 측정한 모세혈 HbA1c와 리튬-헤파린 전혈 HbA1c 사이의 상관계수는 0.9724, LABGEO PT10에서 측정한 EDTA HbA1c와 리튬-헤파린 전혈 HbA1c 사이의 상관계수는 0.9730이었다. 결론: LABGEO PT10은 기존 방법과 비교될만한 적절한 성능으로 당화혈색소를 측정하였으며, 정맥혈을 채혈하기 어려운 상황의 환자들에게 모세혈로 검사함으로써 유용하게 사용될 수 있을 것으로 기대된다.
Abstract
Background: Hemoglobin A1c (HbA1c) is a good marker for monitoring glycemic control. The Samsung LABGEO PT10 HbA1c test (Samsung Electronics, Korea) was developed as a point-of-care testing approach. This study evaluated the levels of HbA1c in three different types of blood specimens using two different methods. Methods: We used correlation analyses to compare the results obtained using Samsung LABGEO PT10 and Bio-Rad Variant II Turbo (Bio-Rad Laboratories, USA) to determine the levels of HbA1c in three different types of blood samples: capillary blood, EDTA whole blood, and lithium (Li)-heparin whole blood. Results: The correlation coefficient for the level of HbA1c in capillary blood based on LABGEO PT10 vs. that in EDTA whole blood based on the Variant II Turbo was r=0.9619; that in capillary blood based on LABGEO PT10 vs. that in Li-heparin whole blood based on the Variant II Turbo was r=0.9619; that in capillary blood vs. that in EDTA whole blood based on the LABGEO PT10 was r=0.9697; that in capillary blood vs. that in Li-heparin whole blood based on the LABGEO PT10 was r=0.9724; and that in EDTA whole blood vs. that in Li-heparin whole blood based on the LABGEO PT10 was r=0.9730. Conclusions: The LABGEO PT10 was suitable for analyzing HbA1c. The results for the measurement of HbA1c levels in capillary blood were comparable to that in the whole blood samples. Additionally, LABGEO PT10 can be used for patients who are unable to take venipuncture.
참고문헌 (16)
- The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
- "WHO diabetes media centre" (2015)[URL]
- Steffes M, "Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study", Clin Chem, 51, pp.753~758 (2005)
- American Diabetes A, "Diagnosis and classification of diabetes mellitus", Diabetes Care, 37(Suppl 1), pp.S81~S90 (2014)
- St John A, "Nurse-based evaluation of point-of-care assays for glycated haemoglobin", Clin Chim Acta, 365, pp.257~263 (2006)
- Miller CD, "Rapid A1c availability improves clinical decision-making in an urban primary care clinic", Diabetes Care, 26, pp.1158~1163 (2003)
- Jeong TD, "Performance evaluation of the LABGEO PT10 point-of-care chemistry analyzer", J Lab Med Qual Assur, 35, pp.70~80 (2013)
- Clinical and Laboratory Standards Institute, "Measurement procedure comparison and bias estimation using patient samples : approved guideline", CLSI, ~ (2013)
- Clinical and Laboratory Standards Institute, "Evaluation of matrix effects : approved guideline", Clinical and Laboratory Standards Institute, ~ (2005)
- Altman DG, "Practical statistics for medical research" (1991), Chapman and Hall
- Solvik UO, "Diagnosing diabetes mellitus: performance of hemoglobin A1c point-of-care instruments in general practice offices", Clin Chem, 59, pp.1790~1801 (2013)
- Weykamp C, "The IFCC Reference Measurement System for HbA1c: a 6-year progress report", Clin Chem, 54, pp.240~248 (2008)
- Little RR, "A review of variant hemoglobins interfering with hemoglobin A1c measurement", J Diabetes Sci Technol, 3, pp.446~451 (2009)
- Bry L, "Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin", Clin Chem, 47, pp.153~163 (2001)
- Sacks DB, "Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus", Clin Chem, 57, pp.e1~e47 (2011)
- Lenters-Westra E, "Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria", Clin Chem, 56, pp.44~52 (2010)